Vertex Pharmaceuticals

Joshua Boger, Ph.D., founded Vertex in 1989 with $6 million in venture capital and a dream to create a new kind of pharmaceutical company. After more than a decade at Merck, where he was told that most of the medicines he would work on would never make it to a patient, he left and founded Vertex with the idea that no challenge should ever be too great. From the very first day, Vertex has pushed the boundaries of what’s possible in medicine with the simple goal of improving the lives of people with serious diseases. Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies.
Company Growth (employees)
Type
Public
HQ
Boston, US
Founded
1989
Size (employees)
2,150 (est)
Website
vrtx.com
Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US

Key People at Vertex Pharmaceuticals

Larry Bock

Larry Bock

Co-Founder
Ian F. Smith

Ian F. Smith

Executive Vice President & CFO
Stuart A. Arbuckle

Stuart A. Arbuckle

Executive Vice President and Chief Commercial Officer
Amit K. Sachdev

Amit K. Sachdev

Senior Vice President,Global Government Strategy, Market Access and Value

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has an office in Boston
Boston, US (HQ)
50 Northern Ave

Vertex Pharmaceuticals Data and Metrics

Vertex Pharmaceuticals Financial Metrics

Vertex Pharmaceuticals's revenue was reported to be $1.7 b in FY, 2016 which is a 65% increase from the previous period.
$, USD

Revenue (FY, 2016)

1.7 b

Revenue growth (FY, 2015 - FY, 2016), %

65%

Net income (FY, 2016)

(84 m)

EBIT (FY, 2016)

9.9 m

Market capitalization (23-Jun-2017)

33.3 b

Closing share price (23-Jun-2017)

135.5

Cash (31-Dec-2016)

1.2 b
Vertex Pharmaceuticals's current market capitalization is $33.3 b.
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.2 b580.4 m1 b1.7 b

Revenue growth, %

(52%)78%65%

Operating expense total

2.1 b1.3 b1.5 b1.7 b

EBIT

(903.4 m)(692.4 m)(466.9 m)9.9 m

EBIT margin, %

(75%)(119%)(45%)1%

Interest expense

22.7 m72.9 m84.2 m81.4 m

Interest income

22.7 m

Pre tax profit

(976.1 m)

Income tax expense

(288.6 m)7 m30.4 m16.7 m

Net Income

(687.6 m)(742.7 m)(588.2 m)(84 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

569.3 m625.3 m714.8 m1.2 b

Accounts Receivable

85.5 m76 m177.6 m201.1 m

Inventories

14.1 m30.8 m57.2 m77.6 m

Current Assets

1.6 b1.5 b1.4 b1.8 b

PP&E

696.9 m715.8 m697.7 m698.4 m

Goodwill

31 m39.9 m50.4 m50.4 m

Total Assets

2.3 b2.3 b2.5 b2.9 b

Accounts Payable

49.3 m71.2 m74.9 m61.5 m

Current Liabilities

397.8 m368.3 m506.3 m792.5 m

Additional Paid-in Capital

5.3 b5.8 b6.2 b6.5 b

Retained Earnings

(4 b)(4.7 b)(5.3 b)(5.4 b)

Total Equity

1.1 b1.3 b

Financial Leverage

2.3 x2.2 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(687.6 m)(742.7 m)(588.2 m)(84 m)

Depreciation and Amortization

48.4 m63.3 m62.3 m61.4 m

Accounts Receivable

53.4 m7.4 m(100 m)(33 m)

Inventories

7.1 m(16 m)(23 m)(16 m)

Accounts Payable

(49.2 m)25 m(1.7 m)(11.7 m)

Cash From Operating Activities

(51.6 m)(513.2 m)(365.4 m)

Cash From Investing Activities

(54.1 m)74 m268.9 m104.5 m

Cash From Financing Activities

180.9 m497.4 m188.9 m133.3 m

Interest Paid

11 m8.7 m85.6 m83.7 m

Income Taxes Paid

2.8 m1.2 m1.8 m
$, USDY, 2016

Revenue/Employee

830.3 k

Financial Leverage

2.2 x

Vertex Pharmaceuticals Market Value History

Vertex Pharmaceuticals Online and Social Media Presence

Vertex Pharmaceuticals News and Updates

Vertex Pharmaceuticals Company Life and Culture

You may also be interested in